NRAS Q61R in mCRC — anti-EGFR (cetuximab/panitumumab) contraindication. Standard chemo ±...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-Q61R-CRC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CRC |
| Sources | SRC-CIVIC SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS Q61R |
| Disease | DIS-CRC |
| ESCAT tier | IB |
| Contraindicated monotherapy | cetuximab / panitumumab (any line) — extended RAS WT required |
| Evidence summary | NRAS Q61R in mCRC — anti-EGFR (cetuximab/panitumumab) contraindication. Standard chemo ± bev; no NRAS-selective drug. |
Notes
ESCAT IB — extended RAS testing is the canonical actionable use of NRAS in mCRC.
Used By
No reverse references found in the YAML corpus.